AstraZeneca PLC (LON:AZN) Receives £145.83 Average PT from Brokerages

AstraZeneca PLC (LON:AZN) has received an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is £145.83.

Several research analysts have issued reports on the stock. Shore Capital Group reiterated a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. Citigroup started coverage on shares of AstraZeneca in a research report on Tuesday, January 27th. They issued a “buy” rating and a £170 price target for the company. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Berenberg Bank boosted their price objective on shares of AstraZeneca from £145 to £160 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. Finally, Jefferies Financial Group restated a “buy” rating and set a £150 target price on shares of AstraZeneca in a report on Monday, November 10th.

Insider Buying and Selling at AstraZeneca

In related news, insider Nazneen Rahman sold 297 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of £134.96, for a total transaction of £40,083.12. 0.15% of the stock is owned by company insiders.

AstraZeneca Price Performance

AZN opened at £153.44 on Friday. The company has a market capitalization of £237.88 billion, a price-to-earnings ratio of 25.49, a PEG ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. AstraZeneca has a 12-month low of GBX 9,573.51 and a 12-month high of £157.32. The business’s fifty day simple moving average is £140.52 and its 200-day simple moving average is £130.43.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.